Combined with pyridoxine (Vitamin B6) as Diclegis (delayed-release) or Bonjesta — the only FDA-approved medication specifically for nausea and vomiting of pregnancy (NVP). Extensive post-marketing surveillance from its earlier formulation (Bendectin) across millions of exposures showed no teratogenicity. Withdrawn from the US market in 1983 due to litigation despite no scientific evidence of harm; re-approved in 2013 after full FDA review.
How it works
Mechanism information is still being processed. Check the DailyMed link in the sidebar for the official prescribing information.
Dosing & administration
Dosing varies by indication and patient profile. Always follow your institution's current prescribing guidelines.
Renal impairment
Consult protocols for adjustment.
Liver impairment
Consult protocols for adjustment.
Use during pregnancy
1st trimester
Safe. First-line pharmacotherapy for NVP. Approved for use from early T1.
2nd trimester
Safe for continued management.
3rd trimester
Safe, though NVP typically resolves. Monitor for sedation.
Clinical note
Combined with pyridoxine (Vitamin B6) as Diclegis (delayed-release) or Bonjesta — the only FDA-approved medication specifically for nausea and vomiting of pregnancy (NVP). Extensive post-marketing surveillance from its earlier formulation (Bendectin) across millions of exposures showed no teratogenicity. Withdrawn from the US market in 1983 due to litigation despite no scientific evidence of harm; re-approved in 2013 after full FDA review.
Breastfeeding
Safe. May cause sedation in infant; monitor.
Warnings & precautions
When not to use it
Avoid in patients with known hypersensitivity to this drug or any of its components.
